Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Proteomics International Laboratories's EBIT per Share for the
six
months ended in Dec. 2025 was A$-0.04.
Its EBIT per Share for the trailing twelve months (TTM) ended in Dec. 2025 was A$-0.09.
During the past 3 years, the average EBIT per Share Growth Rate was -6.20% per year.
During the past 5 years, the average EBIT per Share Growth Rate was -16.40% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.
Proteomics International Laboratories (ASX:PIQ) EBIT per Share Explanation
EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.
Proteomics International Laboratories EBIT per Share Related Terms
Proteomics International Laboratories EBIT per Share Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Proteomics International Laboratories EBIT per Share Chart
EBIT per Share for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was A$-0.09
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Proteomics International Laboratories (ASX:PIQ) has a EBIT per Share of A$-0.09 as of Dec. 2025. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on Proteomics International Laboratories and its competitors. According to the industry distribution chart, Proteomics International Laboratories ranks #904 out of 1173 companies in the Biotechnology industry, placing it in the top 77.1%.
Is Proteomics International Laboratories' EBIT per Share too high?
Proteomics International Laboratories' current EBIT per Share is A$-0.09. Based on the distribution chart, Proteomics International Laboratories ranks #904 out of 1173 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Proteomics International Laboratories has a GF Score™ of 31/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Proteomics International Laboratories' EBIT per Share compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Proteomics International Laboratories ranks #904 out of 1173 companies for EBIT per Share. This places Proteomics International Laboratories in the lower half of its industry. The industry median EBIT per Share is 15.40. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT per Share for a Biotechnology company?
The median EBIT per Share among Biotechnology companies is 15.40, based on 1,173 companies in the industry. Companies in the top quartile (top 25%) have a EBIT per Share significantly above this median, while those in the bottom quartile fall well below. However, EBIT per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT per Share mean?
A high EBIT per Share can signal that a stock is expensive relative to its fundamentals. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on Proteomics International Laboratories and its competitors. For the Biotechnology industry, the median EBIT per Share is 15.40 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Proteomics International Laboratories's current EBIT per Share is A$-0.09. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Proteomics International Laboratories stock overvalued right now?
Based on GuruFocus' analysis, Proteomics International Laboratories (ASX:PIQ) is currently considered Possible Value Trap. The stock's GF Value™ is A$0.48, compared to a current price of A$0.20 — trading 59.4% below its estimated fair value. The current EBIT per Share is A$-0.09. Proteomics International Laboratories' overall GF Score™ is 31/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT per Share calculated?
EBIT per Share is calculated from a company's financial statements. For Proteomics International Laboratories (ASX:PIQ), the current EBIT per Share is A$-0.09 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Proteomics International Laboratories (ASX:PIQ) Overvalued in 2026?
Based on GuruFocus' analysis, Proteomics International Laboratories stock appears to be undervalued.
The current stock price of A$0.20 is trading 59.4% below its estimated GF Value™ of A$0.48.
GuruFocus considers Proteomics International Laboratories to be Possible Value Trap.
Key valuation signals for ASX:PIQ:
EBIT per Share: A$-0.09
GF Value™: A$0.48 vs. price of A$0.20 (59.4% below fair value)
No single metric tells the full story. See the ASX:PIQ stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Proteomics International Laboratories Business Description
Proteomics International Laboratories Ltd is a biological research and drug discovery company. It is a pioneering medical technology company operating at the forefront of predictive diagnostics and precision medicine. The Company specialises in proteomics-the industrial-scale study of the structure and function of proteins. Its pipeline includes Promarker, Pipeline PromarkerD, PromarkerEndo, PromarkerEso, and OxiDx.
31GF Score
Get the complete analysis for ASX:PIQ
EBIT per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:PIQ has been successfully added to your 
